期刊文献+

培美曲塞单药二线治疗肺大细胞癌的疗效及安全性 被引量:3

下载PDF
导出
摘要 目的 为有效缓解肺大细胞癌患者疼痛感,临床探究采用培美曲塞的疗效及安全性。方法 选取我院2014年3月~2015年4月期间96例经诊断为肺大细胞癌的患者,按入院时间进行分配分为多西他赛组48例和培美曲塞组48例。多西他赛组临床注射多西他赛,培美曲塞组采用培美曲塞,观察两组临床有效率(RR)、疾病控制率、疾病进展时间(TTP),统计治疗期间不良反应情况。结果 多西他赛组临床有效率为27.1%,疾病控制率为83.3%,培美曲塞组依次分别为58.3%以及91.7%,多西他赛组较培美曲塞组临床有效率低,P〈0.05,两组临床疾病控制率差别无意义,P〉0.05;培美曲塞组不良反应发生率为14.6%,多西他赛组高达27.1%,多西他赛组较培美组不良反应多,P〈0.05。结论临床在治疗肺大细胞癌患者时使用培美曲塞患者疾病控制效果好、不良反应少、能提高治疗效果。
出处 《海峡药学》 2016年第8期138-139,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献6

二级参考文献55

  • 1顾海,李洪超.药物经济学成本-效果分析应用的相关问题探讨[J].中国药房,2004,15(11):674-676. 被引量:122
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemother- apy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
  • 3Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a rneta-analysis of the lit-erature. Chest, 1994, 106(3): 861-865.
  • 4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18(10): 2098-2103.
  • 5Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer pre- viously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
  • 6Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 7Scagliotti GV, Parikh P, von PawelJ, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21): 3543-3551.
  • 8Sun JM, Lee KW, Kim JH, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol, 2009, 39(1): 27-32.
  • 9Chang MH, Ahn JS, Lee J, et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small-cell lung cancer. Lung Cancer, 2010, 69(3): 323-329.
  • 10Hanna N,Shepherd FA,Fossella FV,et al.Randomized phaseⅢtrial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22(9):1589-1597.

共引文献77

同被引文献30

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部